HemaSeq Dx – Diagnostic kit for hematooncology (Q11306)

From EU Knowledge Graph
Revision as of 15:29, 22 October 2020 by DG Regio (talk | contribs) (‎Created claim: summary (P836): It is a multidisciplinary highly innovative project aimed at developing diagnostic kits for the detection of clinically relevant mutations in chronic lymphocytic leukemia and multiple myeloma, including development of evaluation software for clinical evaluation of mutations. The aim of this industrial development and research is a product of a high degree of specificity and innovation using a new generation sequencing technique with features tha...)
Jump to navigation Jump to search
Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
HemaSeq Dx – Diagnostic kit for hematooncology
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    0 references
    29,985,600.0 Czech koruna
    0 references
    1,199,424.0 Euro
    10 January 2020
    0 references
    48,000,000.0 Czech koruna
    0 references
    1,920,000.0 Euro
    10 January 2020
    0 references
    62.47 percent
    0 references
    1 January 2018
    0 references
    19 April 2020
    0 references
    Institute of Applied Biotechnologies a.s.
    0 references

    50°5'1.93"N, 14°30'28.48"E
    0 references
    10800
    0 references
    Jedná se o multidisciplinární vysoce inovativní projekt zaměřený na vývoj diagnostických souprav pro detekci klinicky relevantních mutací u chronické lymfocytární leukemie a mnohočetného myelomu, včetně vývoje vyhodnocovacího softwaru pro klinické vyhodnocení mutací. Cílem tohoto průmyslového vývoje a výzkumu je produkt vysoké míry specifičnosti a inovativnosti využívající techniku sekvenování nové generace s vlastnostmi, které současný trh nenabízí. a. (Czech)
    0 references
    It is a multidisciplinary highly innovative project aimed at developing diagnostic kits for the detection of clinically relevant mutations in chronic lymphocytic leukemia and multiple myeloma, including development of evaluation software for clinical evaluation of mutations. The aim of this industrial development and research is a product of a high degree of specificity and innovation using a new generation sequencing technique with features that the current market does not offer. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/16_084/0010310
    0 references